GlassScriptPhysician profile
Brandon M Hardesty
NPI 1952581027
$72,464.10
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40K · 2020: $6,213 · 2021: $3,540 · 2022: $12K · 2023: $10K · 2024: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,543 · Travel and Lodging: $1,826 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,728 · Food and Beverage: $1,163 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,543.00 |
| Travel and Lodging | $1,826.46 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,727.50 |
| Food and Beverage | $1,163.46 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $28,346.11 | 2019 | |
| Biomarin Pharmaceutical INC. | $11,706.14 | 2019-2023 | |
| Novo Nordisk INC | $10,552.27 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $7,592.50 | 2020-2021 | |
| Genzyme Corporation | $7,023.51 | 2022-2023 | |
| Novo Nordisk Health Care Ag | $3,240.00 | 2022 | |
| Pfizer INC. | $1,720.90 | 2019 | |
| Alexion Pharmaceuticals, INC. | $1,112.75 | 2022-2023 | |
| Genentech USA, INC. | $400.13 | 2022-2023 | Hemlibra |
| Bayer Healthcare Pharmaceuticals INC. | $386.56 | 2019-2023 | |
| Kedrion Biopharma, INC. | $193.53 | 2022 | |
| Genentech, INC. | $149.78 | 2022 | |
| Scilex Pharmaceuticals INC. | $39.92 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Hardesty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.